Clinical outcomes comparison in diabetic and non-diabetic COVID-19 patients: A case-control study

Muhammad Amjad Kalhoro; Kashif Ali; Imran Khan; Aroon Kumar; Fahad Aman Khan; Hafiz Abdul Rauf

doi:10.53730/ijhs.v6nS8.13167

Authors

Muhammad Amjad Kalhoro
Drmakalhoro80@gmail.com
Assistant Professor Medicine, Liaquat University of Medical and Health Sciences Jamshoro Pakistan
Kashif Ali Assistant Professor Medicine, Bilawal Medical College for boys LUMHS Jamshoro Pakistan
Imran Khan Associate Professor Medicine, Al Aleem Medical College Gulab Devi Teaching Hospital Lahore Pakistan
Aroon Kumar Physician Observer, Penn State Health Holy Spirit Medical Center, Camp Hill, Penssylvania, USA
Fahad Aman Khan Associate Professor Medicine, Al Aleem Medical College Gulab Devi Teaching Hospital Lahore Pakistan
Hafiz Abdul Rauf Assistant Professor Medicine, Al Aleem Medical College Gulab Devi Teaching Hospital Lahore Pakistan

Keywords:

diabetes, COVID-19, morbidity, mortality rate

Abstract

Aim: To compare the clinical outcomes of a severe attack of COVID-19 in patients with diabetes and patients with no diabetes. Study design: A case-control study. Place and Duration: This study was conducted at Liaquat University of Medical and Health Sciences Jamshoro Pakistan from October 2020 to October 2021. Methodology: Out of 62 patients who visited the emergency department during the study period with shortness of breath, 55 participants tested positive for COVID-19. Those 55 were included in the present study. All the patients were admitted to ICU. A detailed demographic and clinical history was taken. All the patients were categorized as diabetic and non-diabetic based on their blood sugar levels. The clinical outcomes were assessed by monitoring blood pressure, rate of shock, renal function tests, and level of troponin. Result: Out of a total of 55 patients, 33 (60%) patients were detected with diabetes and the remaining 22 (40%) did not have diabetes. A total of 21 (63.64%) of the diabetic patients needed invasive ventilation and 9 (27.27%) needed non-invasive ventilation. A total of 20 (60.6%) diabetic patients had acute kidney injury and 29 (87.88%) had elevated levels of troponin.

Downloads

Download data is not yet available.

References

Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes research and clinical practice. 2020 Aug 1; 166:108347.

Badawi A, Ryoo SG. Prevalence of diabetes in the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus: a systematic review and meta-analysis. Journal of public health research. 2016 Dec 21; 5(3): jphr-2016.

Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 8: S9–S14.

Federation ID. IDF diabetes atlas international diabetes federation. Brussels, Belgium, 2015.

Hamano K, Nakadaira I, Suzuki J, Gonai M. N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes. Vascular Health and Risk Management. 2014; 10:585.

Han X, Fan Y, Wan YL, Shi H. A diabetic patient with 2019-nCoV (COVID-19) infection who recovered and was discharged from hospital. Journal of thoracic imaging. 2020 May 1; 35.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15; 395(10223):497-506.

International Diabetes Federation. COVID-19 outbreak: guidance for people with diabetes. News.

Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, Oh DH, Kim JH, Koh B, Kim SE, Yun NR. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. Journal of Korean medical science. 2020 Apr 6; 35(13).

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents. 2020 Mar 1; 55(3):105924.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020 Feb 22; 395(10224):565-74.

Peric S, Stulnig TM. Diabetes and COVID-19. Wiener KlinischeWochenschrift. 2020 Jul; 132(13):356-61.

Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in the prevalence of diabetes in Asian countries. World journal of diabetes. 2012 Jun 6; 3(6):110.

Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S. New-onset diabetes in Covid-19. New England Journal of Medicine. 2020 Aug 20; 383(8):789-90.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010 Jan 1; 87(1):4-14.

Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, Li Y, Li T, Wu C, Wu G, Zhong Y. Epidemiological and clinical features of corona virus disease 2019 (COVID-19) in Changsha, China. China (3/1/2020). 2020 Mar 1.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes research and clinical practice. 2011 Dec 1; 94(3):311-21.

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020 Jul; 75(7):1730-41.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28; 395(10229):1054-62.